Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 192

1.

Structure-Based Virtual Screening for Dopamine D2 Receptor Ligands as Potential Antipsychotics.

Kaczor AA, Silva AG, Loza MI, Kolb P, Castro M, Poso A.

ChemMedChem. 2016 Apr 5;11(7):718-29. doi: 10.1002/cmdc.201500599. Epub 2016 Mar 18.

PMID:
26990027
2.

The Effects of Sequence Variation on Genome-wide NRF2 Binding-New Target Genes and Regulatory SNPs.

Kuosmanen SM, Viitala S, Laitinen T, Peräkylä M, Pölönen P, Kansanen E, Leinonen H, Raju S, Wienecke-Baldacchino A, Närvänen A, Poso A, Heinäniemi M, Heikkinen S, Levonen AL.

Nucleic Acids Res. 2016 Feb 29;44(4):1760-75. doi: 10.1093/nar/gkw052. Epub 2016 Jan 29.

3.

Common and Distinct Interactions of Chemical Inhibitors with Cytochrome P450 CYP1A2, CYP2A6 and CYP2B6 Enzymes.

Raunio H, Juvonen RO, Poso A, Lahtela-Kakkonen M, Rahnasto-Rilla M.

Drug Metab Lett. 2016;10(1):56-64.

PMID:
26648056
4.

Potent and selective N-(4-sulfamoylphenyl)thiourea-based GPR55 agonists.

Yrjölä S, Parkkari T, Navia-Paldanius D, Laitinen T, Kaczor AA, Kokkola T, Adusei-Mensah F, Savinainen JR, Laitinen JT, Poso A, Alexander A, Penman J, Stott L, Anskat M, Irving AJ, Nevalainen TJ.

Eur J Med Chem. 2016 Jan 1;107:119-32. doi: 10.1016/j.ejmech.2015.10.050. Epub 2015 Nov 2.

PMID:
26575458
5.

Time-Dependent Inhibition of CYP2C19 by Isoquinoline Alkaloids: In Vitro and In Silico Analysis.

Salminen KA, Rahnasto-Rilla M, Väänänen R, Imming P, Meyer A, Horling A, Poso A, Laitinen T, Raunio H, Lahtela-Kakkonen M.

Drug Metab Dispos. 2015 Dec;43(12):1891-904. doi: 10.1124/dmd.115.065755. Epub 2015 Sep 23.

PMID:
26400396
6.

Comparative molecular field analysis and molecular dynamics studies of α/β hydrolase domain containing 6 (ABHD6) inhibitors.

Kaczor AA, Targowska-Duda KM, Patel JZ, Laitinen T, Parkkari T, Adams Y, Nevalainen TJ, Poso A.

J Mol Model. 2015 Oct;21(10):250. doi: 10.1007/s00894-015-2789-8. Epub 2015 Sep 8.

7.

Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.

Tervonen TA, Belitškin D, Pant SM, Englund JI, Marques E, Ala-Hongisto H, Nevalaita L, Sihto H, Heikkilä P, Leidenius M, Hewitson K, Ramachandra M, Moilanen A, Joensuu H, Kovanen PE, Poso A, Klefström J.

Oncogene. 2016 Apr 7;35(14):1832-46. doi: 10.1038/onc.2015.248. Epub 2015 Jul 13.

PMID:
26165838
8.

Virtual screening approach of sirtuin inhibitors results in two new scaffolds.

Kokkonen P, Kokkola T, Suuronen T, Poso A, Jarho E, Lahtela-Kakkonen M.

Eur J Pharm Sci. 2015 Aug 30;76:27-32. doi: 10.1016/j.ejps.2015.04.025. Epub 2015 May 1.

PMID:
25936698
9.

Novel fused tetrathiocines as antivirals that target the nucleocapsid zinc finger containing protein of the feline immunodeficiency virus (FIV) as a model of HIV infection.

Asquith CR, Meli ML, Konstantinova LS, Laitinen T, Poso A, Rakitin OA, Hofmann-Lehmann R, Allenspach K, Hilton ST.

Bioorg Med Chem Lett. 2015 Mar 15;25(6):1352-5. doi: 10.1016/j.bmcl.2014.12.047. Epub 2014 Dec 20.

PMID:
25702849
10.

New, non-quinone fluorogeldanamycin derivatives strongly inhibit Hsp90.

Hermane J, Bułyszko I, Eichner S, Sasse F, Collisi W, Poso A, Schax E, Walter JG, Scheper T, Kock K, Herrmann C, Aliuos P, Reuter G, Zeilinger C, Kirschning A.

Chembiochem. 2015 Jan 19;16(2):302-11. doi: 10.1002/cbic.201402375. Epub 2015 Jan 8.

PMID:
25572106
11.

Pharmacological and molecular studies on the interaction of varenicline with different nicotinic acetylcholine receptor subtypes. Potential mechanism underlying partial agonism at human α4β2 and α3β4 subtypes.

Arias HR, Feuerbach D, Targowska-Duda K, Kaczor AA, Poso A, Jozwiak K.

Biochim Biophys Acta. 2015 Feb;1848(2):731-41. doi: 10.1016/j.bbamem.2014.11.003. Epub 2014 Dec 2.

12.

Synthesis, in vitro and in vivo studies, and molecular modeling of N-alkylated dextromethorphan derivatives as non-competitive inhibitors of α3β4 nicotinic acetylcholine receptor.

Jozwiak K, Targowska-Duda KM, Kaczor AA, Kozak J, Ligeza A, Szacon E, Wrobel TM, Budzynska B, Biala G, Fornal E, Poso A, Wainer IW, Matosiuk D.

Bioorg Med Chem. 2014 Dec 15;22(24):6846-56. doi: 10.1016/j.bmc.2014.10.036. Epub 2014 Oct 31.

PMID:
25464883
13.

Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.

Yrjölä S, Sarparanta M, Airaksinen AJ, Hytti M, Kauppinen A, Pasonen-Seppänen S, Adinolfi B, Nieri P, Manera C, Keinänen O, Poso A, Nevalainen TJ, Parkkari T.

Eur J Pharm Sci. 2015 Jan 25;67:85-96. doi: 10.1016/j.ejps.2014.11.003. Epub 2014 Nov 14.

PMID:
25447744
14.

Quantitative insight into the design of compounds recognized by the L-type amino acid transporter 1 (LAT1).

Ylikangas H, Malmioja K, Peura L, Gynther M, Nwachukwu EO, Leppänen J, Laine K, Rautio J, Lahtela-Kakkonen M, Huttunen KM, Poso A.

ChemMedChem. 2014 Dec;9(12):2699-707. doi: 10.1002/cmdc.201402281. Epub 2014 Sep 9.

PMID:
25205473
15.

Identification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis.

Khan SA, Virtanen S, Kallioniemi OP, Wennerberg K, Poso A, Kaski S.

Bioinformatics. 2014 Sep 1;30(17):i497-504. doi: 10.1093/bioinformatics/btu456.

16.

Robust hydrolysis of prostaglandin glycerol esters by human monoacylglycerol lipase (MAGL).

Savinainen JR, Kansanen E, Pantsar T, Navia-Paldanius D, Parkkari T, Lehtonen M, Laitinen T, Nevalainen T, Poso A, Levonen AL, Laitinen JT.

Mol Pharmacol. 2014 Nov;86(5):522-35. doi: 10.1124/mol.114.094284. Epub 2014 Aug 19.

17.

Integrative and personalized QSAR analysis in cancer by kernelized Bayesian matrix factorization.

Ammad-ud-din M, Georgii E, Gönen M, Laitinen T, Kallioniemi O, Wennerberg K, Poso A, Kaski S.

J Chem Inf Model. 2014 Aug 25;54(8):2347-59. doi: 10.1021/ci500152b. Epub 2014 Aug 6.

PMID:
25046554
18.

Evaluation of the antiviral efficacy of bis[1,2]dithiolo[1,4]thiazines and bis[1,2]dithiolopyrrole derivatives against the nucelocapsid protein of the Feline Immunodeficiency Virus (FIV) as a model for HIV infection.

Asquith CR, Meli ML, Konstantinova LS, Laitinen T, Peräkylä M, Poso A, Rakitin OA, Allenspach K, Hofmann-Lehmann R, Hilton ST.

Bioorg Med Chem Lett. 2014 Jun 15;24(12):2640-4. doi: 10.1016/j.bmcl.2014.04.073. Epub 2014 Apr 26.

PMID:
24813732
19.

Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910.Na.

Mäki-Jouppila JH, Laine LJ, Rehnberg J, Narvi E, Tiikkainen P, Hukasova E, Halonen P, Lindqvist A, Kallio L, Poso A, Kallio MJ.

Mol Cancer Ther. 2014 May;13(5):1054-66. doi: 10.1158/1535-7163.MCT-13-0685. Epub 2014 Apr 18.

20.

Quantitative insights for the design of substrate-based SIRT1 inhibitors.

Kokkonen P, Mellini P, Nyrhilä O, Rahnasto-Rilla M, Suuronen T, Kiviranta P, Huhtiniemi T, Poso A, Jarho E, Lahtela-Kakkonen M.

Eur J Pharm Sci. 2014 Aug 1;59:12-9. doi: 10.1016/j.ejps.2014.04.003. Epub 2014 Apr 18.

PMID:
24747578
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk